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Background: Numerous efficacious chemotherapy regimens may cause thrombocytopenia. Thrombopoietin
receptor (TPO-R) agonists, such as eltrombopag, represent a novel approach for the treatment of
chemotherapy-induced thrombocytopenia. The TPO-R MPL is expressed on megakaryocytes and megakaryocyte
precursors, although little is known about its expression on other tissues.
Methods: Breast, lung, and ovarian tumor samples were analyzed for MPL expression by microarray and/or
quantitative reverse transcription-polymerase chain reaction (qRT-PCR), and for TPO-R protein expression by
immunohistochemistry (IHC). Cell line proliferation assays were used to analyze the in vitro effect of eltrombopag
on breast, lung, and ovarian tumor cell proliferation. The lung carcinoma cell lines were also analyzed for TPO-R
protein expression by Western blot.
Results: MPL mRNA was not detectable in 118 breast tumors and was detectable at only very low levels in 48% of
29 lung tumors studied by microarray analysis. By qRT-PCR, low but detectable levels of MPL mRNA were detectable
in some normal (14-43%) and malignant (3-17%) breast, lung, and ovarian tissues. A comparison of MPL to EPOR,
ERBB2, and IGF1R mRNA demonstrates that MPL mRNA levels were far lower than those of EPOR and ERBB2 mRNA
in the same tissues. IHC analysis showed negligible TPO-R protein expression in tumor tissues, confirming mRNA
analysis. Culture of breast, lung, and ovarian carcinoma cell lines showed no increase, and in fact, showed a
decrease in proliferation following incubation with eltrombopag. Western blot analyses revealed no detectable
TPO-R protein expression in the lung carcinoma cell lines.
Conclusions: Multiple analyses of breast, lung, and ovarian tumor samples and/or cell lines show no evidence of
MPL mRNA or TPO-R protein expression. Eltrombopag does not stimulate growth of breast, lung, or ovarian tumor
cell lines at doses likely to exert their actions on megakaryocytes and megakaryocyte precursors.Background
Breast cancer is the most commonly occurring neoplasm
and the second leading cause of cancer deaths in
women. Lung cancer is the second most frequent cancer
diagnosis in men and women, and remains the leading
cause of cancer deaths. Although ovarian cancer affects
fewer women than breast or lung cancer, it is one of the
most lethal types of cancer [1]. Current clinical guidelines
recommend platinum-containing chemotherapy regimens,* Correspondence: connie.l.erickson-miller@gsk.com
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distribution, and reproduction in any mediumamong others, for these malignancies in different disease
stages [2-7]. Established treatment protocols may be
associated with a range of adverse events (AEs), including
thrombocytopenia, anemia, and neutropenia. Newer
chemotherapy combinations including carboplatin plus
pemetrexed or gemcitabine in non-small cell lung cancer
(NSCLC) may also be associated with high rates of
thrombocytopenia [8].
Thrombocytopenia may lead to significant clinical con-
sequences including petechiae, gastrointestinal bleeding,
and bleeding into the brain [9]. Neutropenia, anemia, or
thrombocytopenia resulting from bone marrow suppres-
sion can delay chemotherapy administration and/or mayCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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on disease control [10]. The use of hematopoietic growth
factors has ameliorated this problem to some degree with
respect to red and white blood cell production [11,12].
However, there are concerns that some growth factors
could induce proliferation of other cell types, including
tumor cells [13,14].
Thrombopoietin (TPO) is a critical cytokine regulating
thrombopoiesis. It is the endogenous ligand for the
thrombopoietin receptor (TPO-R) MPL expressed on
the surface of megakaryocytes, megakaryocyte precur-
sors, and platelets [15-18]. TPO-R agonists are approved
for the treatment of chronic immune thrombocytopenia
(ITP). The interaction of the selective, nonpeptidyl TPO-R
agonist, eltrombopag, with TPO-R triggers activation of
the JAK-STAT and MAP kinase, but not the AKT, signal
transduction pathways. This causes alterations in gene
expression patterns to promote megakaryocytic differen-
tiation and maturation, resulting in increased platelet
counts [19,20]. There are differences between the ampli-
tude and extent of signaling between TPO and eltrombo-
pag [21]. Acute myeloid leukemia (AML) blasts have
been shown to express TPO-R [22] and in some reports
TPO has induced proliferation of these blasts [23],
although investigations in leukemia cell lines show
conflicting results [24,25]. A variety of human non-
megakaryocytic leukemia and lymphoma cell lines show
decreased, rather than increased, proliferation upon in-
cubation with eltrombopag [26]. In vitro and in vivo ana-
lyses of bone marrow mononuclear cells from patients
with AML and myelodysplastic syndromes (MDS) simi-
larly showed no increase in proliferation with eltrombo-
pag treatment [25,27].
The objective of this study was to determine whether
solid tumors (i.e., breast, lung, and ovarian) express MPL
mRNA or TPO-R protein, and whether eltrombopag
affects the proliferation of solid tumor cell lines. Ex-
pression of MPL mRNA was assessed by microarray
analysis in breast and lung tumor samples and by quanti-
tative reverse transcription-polymerase chain reaction
(qRT-PCR) in normal and malignant tissue samples from
breast, lung, and ovary. TPO-R protein expression was
determined by immunohistochemistry (IHC) on breast,
lung, and ovarian tumor samples and by western blot
on lung cell lines. Cell proliferation in response to




In accordance with the Helsinki Declaration, all patients
provided written informed consent for use of their sam-
ples, and the collection and use of the samples received
Institutional Review Board (IRB) approval.Microarray analysis
Experimental samples
Archival tissue samples from 118 patients who had lo-
cally advanced or metastatic breast cancer and had failed
treatment with anthracycline-, taxane-, and trastuzumab-
containing regimens were studied. Specimens were
obtained from patients who had histologically confirmed
invasive breast cancer with Stage IIIB, Stage IIIC with T4
lesion, or Stage IV disease (GSK Study EGF100151), with
documentation of ERBB2 overexpression (IHC 3+ or
IHC 2+ with fluorescence in situ hybridization [FISH]
confirmation) [28,29]. Microarray analysis was performed
at Response Genetics, Inc (Los Angeles, CA, USA).
Frozen tissue samples from 29 patients who were pre-
surgical, treatment-naive, with Stage IA or Stage IB, re-
sectable NSCLC were studied (GSK Study VEG105290).
Microarray analysis was performed at Weill Medical
College of Cornell University (New York, NY, USA).
Experimental protocol
Archival breast tumor specimens were formalin-fixed
and embedded in paraffin. The quality of tumor tissue
RNA extraction was assessed by laser capture microdis-
section. Reverse transcription-polymerase chain reaction
(RT-PCR) for 300 base pair (bp) of the β-actin gene was
used for quality control of these samples. Samples with a
cycle time (CT) of < 32 at the 300 bp level were accept-
able for microarray analysis. mRNA and cDNA were
prepared from archival breast tumor tissues and frozen
NSCLC samples using the Affymetrix HG-U133 Plus2
array (Affymetrix, Inc., Santa Clara, CA, USA). RNA mi-
croarray gene signal intensity was normalized using the
robust microchip analysis (RMA) method described by
Irizarry et al [30]. Samples with RMA< 50 are below the
level of detection by this method.
qRT-PCR analysis
Experimental samples
Samples of normal tissue cDNA and tumor tissue cDNA
were obtained from Cytomyx (Lexington, MA, USA).
Seven samples of normal breast tissue were studied, and
41 breast carcinoma samples, including tissue from can-
cers of Stage I, Stage II, and Stage IIIB were analyzed.
Eight normal lung specimens and lung tissue samples
from 40 tumors, ranging from Stages IA to IV were ex-
amined. Ovarian samples included 7 normal ovarian tis-
sues and 41 ovarian tumors ranging from Stages I to IV.
Experimental protocol
MPL gene expression was measured using FAM-TAMRA-
labeled primers and probes in a 7900HT thermal cycler
using a standard 40-cycle profile with 9600 emulation.
Following amplification, calculations were performed to
determine the relative abundance of MPL normalized to
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hydrogenase (GAPDH), β-actin (ACTB), and cyclophilin
A (PPIA). Each result is presented as a normalized value
of mRNA. EPOR, ERBB2, and IGF1R were also assessed
to provide data for comparable receptors. Primers and
probes were custom made by Integrated DNA Technolo-
gies (Coralville, IA, USA). Sequences for the primers and
probes were previously described [31] and are listed in
Additional file 1: Table S1.
qRT-PCR data analysis
CT values for genes of interest were normalized to the
internal housekeeping genes run in the reaction using
in-house software. Raw abundance value was calculated
using the following equation: Abundance = 10e[(40-CT)/
3.35]. Samples were scaled relative to each other using
the geometric mean of the set of valid housekeeping
gene data points for that sample. Each data point was
then expressed as the ratio of the housekeeping gene
abundance in the sample to the average of that house-
keeping gene in all samples and marked invalid if it had
statistically inconsistent behavior with the other house-
keeping genes in those samples of similar tissue types.
Samples with a relative abundance of < 50 are below the
level of detection of this method.
IHC for TPO-R protein expression
Experimental samples
Formalin-fixed, paraffin embedded (FFPE) controls and
FFPE specimens of breast, lung, and ovarian cancer were
procured by Mosaic Laboratories under an IRB-reviewed
protocol that allows for use of remnant, de-identified, or
anonymized human samples for in vitro analysis under
the guidelines defining Exemption from Human Subject
Research as defined by the Office of Human Research
Protection. FFPE tissue samples of breast, lung, and ovar-
ian cancer were also procured from OriGene (formerly
Cytomyx) for analysis. A FFPE block of N2C-Tpo cells, a
Tpo-dependent megakaryocytic leukemia cell line, and of
normal bone marrow were used as positive controls for
TPO-R expression.
Experimental protocol
Immunohistochemical analysis was performed in accord-
ance with Mosaic Laboratories’ Standard Operating Pro-
cedures. Briefly, the procedure was performed manually
using the Envision™ system and ancillary reagents (Dako,
Carpinteria, CA). Specimens were sectioned at a thick-
ness of 4 microns, mounted onto positive-charged glass
slides, dried, deparaffinized, and rehydrated. Following
rehydration, tissue sections were incubated in Envision
peroxidase for 5 minutes to quench endogenous perox-
idase. Heat-induced epitope retrieval was performed
using Rip Tide buffer for 40 minutes at 95°C. Slides wereincubated with anti-CD110 antibody (clone 1.78.1) (BD
Biosciences) diluted in diluent (Dako) for 30 minutes.
Slides were then rinsed twice in Splash-T buffer for
5 minutes each. Signal was visualized using Envision +
Mouse HRP detection reagent (Dako) for 30 minutes,
followed by 3,3 diamino benzidine according to manu-
facturer’s instructions. Slides were rinsed with water,
counterstained with hematoxylin (Dako), dehydrated
through graded alcohols, cleared in xylene, and cover-
slipped for microscopic evaluation.
Data analysis
Staining was evaluated by a pathologist; evaluation of
reactivity involved a combination of the following: cel-
lular localization of staining, staining intensity, subcel-
lular localization, and percentage of cells staining in
the primary component of the tissue type of interest.
The CD110 IHC assay was scored on a semi-quantitative
scale, and the percentage of cancer cells staining at each of
the following 4 levels was recorded: 0 (unstained), 1+
(weak staining), 2+ (moderate staining), and 3+ (strong
staining). An H-score was calculated based on the summa-
tion of the product of percent of cells stained at each in-
tensity, using the following equation: (3×% cells staining
at 3+) + (2×% cells staining at 2+) + (1×% cells staining at
1+). H-score values range from 0–300. (Additional file 2:
Table S2).
Cell line proliferation assays
Experimental preparations
Cell lines were obtained from the American Type Culture
Collection (Walkersville, MD, USA). All cells were main-
tained in log-phase growth in their respective media. The
breast cancer cell lines (MCF-7, BT474, and HCC1937),
lung cancer cell lines (A549, NCI-H226, NCI-H460,
and NCI-H510), and ovarian cell lines (OVCAR4 and
SKOV-3) were grown in RPMI 1640 medium with 10%
fetal calf serum (FCS). The ovarian carcinoma cell line
OVCAR3 was grown in RPMI 1640 medium with 20%
FCS, 1% sodium pyruvate, and 1% v/v glutamine.
All experiments were performed with milled, mono-
ethanolamine salt form SB-497115-GR (eltrombopag)
resuspended in water to 10 mg/mL, and diluted in
Iscove’s Modified Dulbecco’s Medium (IMDM) with 1%
FCS. Recombinant human TPO (rhTPO) was purchased
from R&D Systems (Minneapolis, MN, USA) and diluted
in IMDM.
Experimental protocols
Cells for the Cell Titer GloW assay were plated at 1 × 103
cells/well in 96-well plates in medium containing 10%
FCS and allowed to adhere for 24 hours. Cells were treated
with eltrombopag at 0, 0.1, 0.4, 1, 4, 10, and 40 μg/mL.
In breast and ovarian cancer cell lines, eltrombopag was
Table 1 Expression of detectable levels of MPL, EPOR,
ERBB2, and IGF1R mRNA in primary tumors of breast and
NSCLC origin by microarray analysis
Breast N= 118 n (%) NSCLC N=29 n (%)
MPL 0 (0) 14 (48)
EPOR 89 (75) 29 (100)
ERBB2 118 (100) 28 (97)
IGF1R 102 (86) 29 (100)
NSCLC, non-small cell lung cancer. Data are represented as number of tumors
with detectable (RMA ≥ 50) expression and percent of tumor type with
detectable expression in parenthesis.
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tested in these experiments. Cells were incubated for
72 hours at 37°C in 5% CO2 after the addition of eltrom-
bopag or rhTPO. Active cell determinations were per-
formed using the Cell Titer GloW reagent (Promega,
Madison, WI, USA) according to the manufacturer’s
protocol. Results were reported as relative luminescence
units (RLU).
Data analysis
The calculated mean and standard deviations were pro-
duced using triplicate samples for each experiment. The
IC50 was determined using XLfit version 4.2.1, utilizing
the best fit model for each data set.
Western blotting for TPO-R protein expression
Experimental preparations
Lung cancer cell lines, A549, NCI-H226, NCI-H460, and
NCI-H510, were grown as described above.
Experimental protocol
Western blots for TPO-R protein expression were per-
formed on reduced cell lysates of log-phase growth lung
cancer cell lines (50 μg/well) on a NuPage 4-12% Bis-
Tris gel (Invitrogen, Carlsbad, CA, USA) with MOPS
running buffer. Precision Protein Dual Color Standards
(Bio-Rad, Hercules, CA, USA) were used. The gels were
transferred to nitrocellulose and stained with a rabbit
polyclonal anti-TPO-R primary antibody (Upstate Biotech-
nology Inc., Lake Placid, NY, USA; Cat# 06–944) and
analyzed with an OdysseyW infrared imager (LI-COR Bios-
ciences, Lincoln, NE, USA).
Results and discussion
MPL expression by microarray analysis
None of the 118 advanced or metastatic breast cancer
samples expressed detectable levels of MPL mRNA; all
samples had RMA< 50. EPOR mRNA was expressed at
detectable levels in 89/118 (75%); all 118 (100%) demon-
strated detectable levels of ERBB2 mRNA; and 102/118
(86%) expressed detectable levels of IGF1R mRNA
(Table 1, Figure 1). ERBB2 mRNA was expressed at the
highest level compared with MPL, EPOR, and IGF1R
mRNA levels.
Of the 29 samples of NSCLC studied by microarray,
14 (48%) expressed low but detectable levels of MPL
mRNA (Table 1, Figure 1). All 29 samples (100%) ex-
pressed EPOR mRNA; 28 of 29 (97%) expressed ERBB2
mRNA, and all 29 (100%) expressed IGF1R mRNA.
MPL expression by qRT-PCR analysis
A more accurate quantitation of MPL expression was
undertaken using qRT-PCR. MPL expression was lower
in both normal and malignant breast tissue thanexpression of EPOR, ERBB2, and IGF1R (Table 2,
Figures 2A and 3A). One of 7 (14%) normal breast tissue
samples studied and 1/40 (3%) breast tumor samples
demonstrated detectable MPL mRNA expression
(Table 2, Figures 2A and 3A). EPOR mRNA expression
was observed in 7/7 (100%) normal breast samples,
and in 32/40 (80%) breast cancer samples. Four of 7
(57%) normal breast tissue samples and 33/40 (83%)
breast tumor samples demonstrated detectable ERBB2
expression. IGF1R expression was detected in 2/7 (29%)
normal breast tissue samples and in 15/40 (38%) breast
cancer samples.
Detectable MPL expression was observed using qRT-
PCR in 1/8 (13%) normal lung tissue samples, and in
1/40 (3%) lung tumor samples. The level of MPL expres-
sion was equivalent in the normal lung tissue and in the
positive tumor sample (Table 2, Figures 2B and 3B). The
lung tumor sample that expressed detectable MPL
mRNA also expressed EPOR mRNA at levels greater
than did other lung tumor samples. EPOR mRNA ex-
pression was identified in all 8 (100%) normal lung sam-
ples, and in 28/40 (70%) lung tumor samples studied.
ERBB2 mRNA expression was detected in all 8 (100%)
normal samples and in 22/40 (55%) lung tumor samples.
In contrast, IGF1R mRNA expression was identified at
detectable levels in only 1/8 (13%) normal lung samples
and 2/40 (5%) lung tumor samples studied (Table 2,
Figures 2B and 3B).
Three of 7 (43%) normal ovarian tissue samples
expressed detectable MPL mRNA and 3/41 (7 %) ovarian
tumor samples had detectable MPL mRNA. Relative ex-
pression of MPL was similar or greater in the positive
normal ovary and ovarian tumor samples (Table 2,
Figures 2C and 3C). All 7 (100%) normal ovary samples
and all 41 (100%) ovarian tumors studied expressed
EPOR mRNA. ERBB2 expression was also observed in
all 7 (100%) normal samples and in 39/41 (95%) tumor
samples. IGF1R expression was not detected in the 7
normal ovarian samples, and was detectable in 7/41
(17%) ovarian tumors studied. Expression of MPL and
IGF1R mRNA was low compared with EPOR and ERBB2
mRNA levels in normal ovary and ovarian tumor samples
Figure 1 Expression of MPL mRNA message determined by microarray analysis, compared to EPOR, ERBB2, and IGF1R message levels
in (A) 118 breast cancer tumor samples (Study EGF100151) and (B) 29 non-small cell lung carcinoma tumor samples (Study
VEG105290). (A). Breast cancer. (B). Non-small cell lung carcinoma.
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mRNA expression in the tumor samples to determine any
relationship between MPL expression levels and stage of
cancer in these breast, lung, or ovarian samples (Figure 3).TPO-R protein expression by IHC
Immunohistochemical analysis examining multiple fields
of FFPE samples of breast, lung, and ovarian patient
tissue stained with the anti-TPO-R antibody (CD110)
Table 2 Expression of detectable levels (abundance ≥ 50) of MPL, EPOR, ERBB2, and IGF1R mRNA in normal tissue and
tumor samples by qRT-PCR
Breast normal








N= 7 n (%)
Ovarian tumor
N=41 n (%)
MPL 1 (14) 1 (3) 1 (13) 1 (3) 3 (43) 3 (7)
EPOR 7 (100) 32 (80) 8 (100) 28 (70) 7 (100) 41 (100)
ERBB2 4 (57) 33 (83) 8 (100) 22 (55) 7 (100) 39 (95)
IGF1R 2 (29) 15 (38) 1 (13) 2 (5) 0 (0) 7 (17)
Quantitative reverse transcription-polymerase chain reaction was used to measure abundance of these genes. Data are represented as number of samples with
detectable expression and percent of the samples in parenthesis.
Figure 2 Relative abundance of MPL mRNA expression determined by qRT-PCR in normal (red bars) and tumor (blue bars) samples.
Abundance is normalized to GAPDH, β-actin, and cyclophilin. The dashed line represents the mean of the normal samples. The gray box
represents relative abundance below the level of accurate detection (abundance < 50). (A). Breast. (B). Lung. (C). Ovarian.
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Figure 3 Relative abundance of MPL, EPOR, ERBB2, and IGF1R
mRNA expression determined by qRT-PCR in normal and tumor
samples. Abundance is normalized to GAPDH, β-actin, and
cyclophilin. Red bars are normal samples, blue bars are tumor
samples. Relative abundance below 50 is below the level of
detection. (A). Breast tumor taqman. (B). Lung tumor taqman.
(C). Ovarian tumor taqman.
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tumor section showed a 1+ signal in one of infiltrat-
ing inflammatory cell, but no staining of tumor cells
was noted. (Figure 4 and Additional file 2: Table S2).
As expected, the positive controls of normal bone
marrow megakaryocytes and the N2C-Tpo cell line
(Figure 4 bottom panels) demonstrated robust specific
staining with the antibody.Cell line proliferation assays
Given that the expression of mRNA does not always
reflect the expression of protein, several breast, lung,
and ovarian cancer cell lines were chosen to assess the
effects of eltrombopag on proliferation using the Cell
Titer Glo assay. Three different breast cancer cell lines
MCF-7, BT474, and HCC1937 were incubated with
eltrombopag for 72 hours to determine whether this
compound stimulated proliferation of breast cancer
cells. The MCF-7 cell line data are shown as a repre-
sentative experiment in Figure 5A. No increase in cell
number was observed in the 3 breast cancer cell lines
with eltrombopag (0.1-100 μg/mL); in fact, all of them
showed a decrease in cell number at eltrombopag
concentrations > 4 μg/mL. Recombinant TPO did not in-
crease or decrease proliferation of any of these breast
cancer cell lines (data not shown). Table 3 shows the
IC50 of eltrombopag on these cell lines: 19.0 μg/mL for
MCF-7; 9.6 μg/mL for BT474; and 10.7 μg/mL for
HCC1937.
Four lung carcinoma cell lines were studied to de-
termine whether eltrombopag stimulated proliferation
including 3 NSCLC (A549, from an alveolar cell car-
cinoma; NCI-H226, from a squamous cell carcinoma;
and NCI-H460, from a large cell carcinoma) and a small
cell lung carcinoma cell line, NCI-H510. There was no
increase in cell number over 72 hours of treatment with
eltrombopag at concentrations from 0.1 μg/mL to
40 μg/mL in any of the 4 lung carcinoma cell lines. The
response of NCI-H226 to eltrombopag is shown in
Figure 5B. All cell lines showed a decrease in cell num-
ber at higher concentrations of eltrombopag (>4 μg/mL).
Recombinant TPO did not affect the proliferation, either
positively or negatively, of any of these cell lines (data
not shown). As shown in Table 3, the IC50 of eltrombo-
pag on these cell lines was 9.0 μg/mL for A549; 3.7 μg/mL
Figure 4 Immunohistochemistry staining of breast, lung, and ovarian tumor samples for TPO-R. Bottom panel: specific staining of
megakaryocytes in normal bone marrow with anti-CD110 (TPO-R) versus the isotype control (IgG) and staining of positive control N2C-Tpo
cell line.
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for NCI-H510.
None of the ovarian carcinoma cell lines (OVCAR3,
OVCAR4, and SKOV-3) demonstrated increased pro-
liferation in response to 0.1 μg/mL to 100 μg/mL
eltrombopag treatment over 72 hours. For all 3 cell
lines, cell number decreased at eltrombopag concen-
trations > 4 μg/mL. A representative experiment dem-
onstrating the response of OVCAR3 cells is shown in
Figure 5C. Recombinant TPO had no positive or nega-
tive proliferative effect on these cell lines (data not
shown). As shown in Table 3, the IC50 of eltrombopag
on these cell lines was 4.8 μg/mL for OVCAR3,
11.0 μg/mL for OVCAR4, and 49.7 μg/mL for SKOV-3.Cell line TPO-R protein expression
We had previously noted that NCI-H510, the cell line
derived from small cell lung carcinoma, expressed high
levels of MPL mRNA by qRT-PCR [31]. We sought to
determine whether mRNA expression correlated with
TPO-R protein expression using Western blots of cell
lysates of lung cancer cell lines treated with eltrombo-
pag. In NCI-H510 cell lysates, no band corresponding to
TPO-R protein was detected. Human platelets and the
megakaryocytic cell lines N2C-Tpo and HEL92.1.7 had
high levels of MPL mRNA and TPO-R protein (Figure 6).
NCI-H226 and NCI-H460 cell lines did not express de-
tectable MPL mRNA by qRT-PCR, nor did they demon-
strate TPO-R protein on Western blots. Western blots
Figure 5 Representative experiment demonstrating the effect
of eltrombopag on proliferation of breast (MCF-7), lung (A549),
and ovarian (OVCAR3) carcinoma cell lines. Data are reported as
relative luminescence units (RLU). (A). MCF-7, breast cell line. (B).
NCI-H226 cells, lung squamous carcinoma cell line. (C). OVCAR3,
ovarian carcinoma cell line.
Table 3 IC50 of proliferation of eltrombopag on breast,
lung, and ovarian tumor cell lines
Cell line Tumor type IC50 (μg/mL)
MCF-7 Breast carcinoma 19.0
BT474 Breast carcinoma 9.6
HCC1937 Breast carcinoma 10.7
A549 Lung alveolar cell carcinoma 9.0
NCI-H226 Lung squamous cell carcinoma 3.7
NCI-H460 Large cell lung carcinoma 8.1
NCI-H510 Small cell lung carcinoma 10.3
OVCAR3 Ovarian adenocarcinoma 4.8
OVCAR4 Ovarian carcinoma 11.0
SKOV-3 Ovarian adenocarcinoma 49.7
Figure 6 Western blot of TPO-R protein expression in lung
carcinoma cell lines.
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TPO-R in NCI-510 and NCI-H226 cell lysates that is
also present in N2C-Tpo and HEL92.1.7 lysates, but the
identity of this band is unknown.
Thrombocytopenia is commonly observed during
treatment with a number of chemotherapy regimens
approved or in development for the treatment of breast,lung, and ovarian cancers [8,32-36]. Identification and
characterization of novel, safe, and effective thrombo-
poietic agents to ameliorate thrombocytopenia remains
an intense area of research [20]. Eltrombopag interacts
with TPO-R, stimulates megakaryopoiesis, and promotes
platelet production and maturation. Although MPL is
expressed on megakaryocytes and megakaryocyte pre-
cursors [15-18], little quantitative data are available on
MPL expression in other tissues.
In this study, MPL expression was compared with ex-
pression of other genes (EPOR, ERBB2, and IGF1R),
which have been widely reported [37-42]. Our analyses
showed that MPL was not commonly expressed at de-
tectable levels in tumor samples as measured by qRT-
PCR. Using microarray analyses, MPL expression was
lower than other cell surface receptors. Even when pro-
tein is expressed, it may not be folded properly to allow
ligand interactions. For example, although MPL is ex-
pressed on leukemic blasts from patients with AML [23],
no proliferation in response to eltrombopag in bone mar-
row mononuclear cells from patients with AML or MDS
has been observed [26]. Nor did eltrombopag stimulate
proliferation in a variety of non-megakaryocytic leukemia
and lymphoma cell lines; decreased proliferation was ob-
served at physiologically achievable eltrombopag con-
centrations (≥ 4 μg/mL) [19]. The observed median
Cmax for eltrombopag in patients with ITP is 11.4 μg/mL
at the 75-mg dose [19], while in patients with chemotherapy-
induced thrombocytopenia, the observed median Cmax
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mately 9.90 μg/mL (unpublished data). Therefore, the
dose at which tumor cell line growth declines is in a
physiologically achievable range. Further studies are
needed to determine whether eltrombopag affects tumor
growth in vivo.
Conclusions
Eltrombopag did not stimulate growth of breast, lung, or
ovarian cancer cell lines at doses likely to exert action
on megakaryocytes and megakaryocyte precursors. Tu-
mor samples of these types had very little, or no, MPL
mRNA or TPO-R protein expression as determined by
qRT-PCR or IHC, respectively.
Additional files
Additional file 1: Table S1. Sequences of primers and probes utilized
in qRT-PCR analyses. qRT-PCR, quantitative reverse transcription-
polymerase chain reaction.
Additional file 2: Table S2. Pathologists review of
immunohistochemistry slides.
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